BackgroundLimited responses have been observed in patients treated with enzalutamide after disease progression on abiraterone for metastatic castration-resistant prostate cancer (mCRPC), but androgen receptor signaling impacts T-cell function. ObjectiveTo evaluate the efficacy and safety of pembrolizumab plus enzalutamide in mCRPC. Design, setting, and participantsPatients in cohort C of the phase 1b/2 KEYNOTE-365 study, who received ≥4 wk of treatment with abiraterone acetate in the prechemotherapy mCRPC state and experienced treatment failure or became drug-intolerant, were included. InterventionPembrolizumab 200 mg intravenously every 3 wk plus enzalutamide 160 mg orally once daily. Outcome measurements and statistical analysisThe primary endpoints were safety, the confirmed prostate-specific antigen (PSA) response rate, and the objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors version 1.1 on blinded independent central review (BICR). Secondary endpoints included radiographic progression-free survival (rPFS) on BICR and overall survival (OS). Results and limitationsA total of 102 patients received pembrolizumab plus enzalutamide. Median follow-up was 51 mo (interquartile range 37–56). The confirmed PSA response rate was 24% (95% confidence interval [CI] 16–33%). The confirmed ORR was 11% (95% CI 2.9–25%; 4/38 patients; two complete responses). Median rPFS was 6.0 mo (95% CI 4.1–6.3). Median OS was 20 mo (95% CI 17–24). Treatment-related adverse events (TRAEs) occurred in 94 patients (92%); grade 3–5 TRAEs occurred in 44 patients (43%). The incidence of treatment-related rash was higher with combination therapy than expected from the safety profile of each drug. One patient (1.0%) died of a TRAE (cause unknown). Study limitations include the single-arm design. ConclusionsPembrolizumab plus enzalutamide had limited antitumor activity in patients who received prior abiraterone treatment without previous chemotherapy for mCRPC, with a safety profile consistent with the individual profiles of each agent. Patient summaryPembrolizumab plus enzalutamide showed limited antitumor activity and manageable safety in patients with metastatic castration-resistant prostate cancer.The KEYNOTE-365 trial is registered on ClinicalTrials.gov as NCT02861573.